These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26743033)

  • 1. Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.
    Hristodorov D; Mladenov R; Fischer R; Barth S; Thepen T
    Immunol Cell Biol; 2016 May; 94(5):470-8. PubMed ID: 26743033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
    Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
    MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
    Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T
    Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice.
    Ribbert T; Thepen T; Tur MK; Fischer R; Huhn M; Barth S
    Br J Dermatol; 2010 Aug; 163(2):279-86. PubMed ID: 20426788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
    Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
    Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies.
    Hristodorov D; Mladenov R; von Felbert V; Huhn M; Fischer R; Barth S; Thepen T
    MAbs; 2015; 7(5):853-62. PubMed ID: 26218624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
    Mladenov R; Hristodorov D; Cremer C; Gresch G; Grieger E; Schenke L; Klose D; Amoury M; Woitok M; Jost E; Brümmendorf TH; Fendel R; Fischer R; Stein C; Thepen T; Barth S
    Oncotarget; 2016 Oct; 7(41):67166-67174. PubMed ID: 27564103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolution of cutaneous inflammation after local elimination of macrophages.
    Thepen T; van Vuuren AJ; Kiekens RC; Damen CA; Vooijs WC; van De Winkel JG
    Nat Biotechnol; 2000 Jan; 18(1):48-51. PubMed ID: 10625390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.
    Stahnke B; Thepen T; Stöcker M; Rosinke R; Jost E; Fischer R; Tur MK; Barth S
    Mol Cancer Ther; 2008 Sep; 7(9):2924-32. PubMed ID: 18790773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin.
    van Roon JA; van Vuuren AJ; Wijngaarden S; Jacobs KM; Bijlsma JW; Lafeber FP; Thepen T; van de Winkel JG
    Arthritis Rheum; 2003 May; 48(5):1229-38. PubMed ID: 12746896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo.
    Hristodorov D; Mladenov R; Pardo A; Pham AT; Huhn M; Fischer R; Thepen T; Barth S
    Br J Cancer; 2013 Sep; 109(6):1570-8. PubMed ID: 23942071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.
    Hristodorov D; Amoury M; Mladenov R; Niesen J; Arens K; Berges N; Hein L; Di Fiore S; Pham AT; Huhn M; Helfrich W; Fischer R; Thepen T; Barth S
    Mol Cancer Ther; 2014 Sep; 13(9):2194-202. PubMed ID: 24980949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice.
    Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED
    J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein.
    Goldstein J; Graziano RF; Sundarapandiyan K; Somasundaram C; Deo YM
    J Immunol; 1997 Jan; 158(2):872-9. PubMed ID: 8993006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential.
    Cremer C; Vierbuchen T; Hein L; Fischer R; Barth S; Nachreiner T
    J Immunother; 2015 Apr; 38(3):85-95. PubMed ID: 25710248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model.
    van Vuuren AJ; van Roon JA; Walraven V; Stuij I; Harmsen MC; McLaughlin PM; van de Winkel JG; Thepen T
    J Immunol; 2006 May; 176(10):5833-8. PubMed ID: 16670289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.
    Schiffer S; Rosinke R; Jost E; Hehmann-Titt G; Huhn M; Melmer G; Barth S; Thepen T
    Int J Cancer; 2014 Sep; 135(6):1497-508. PubMed ID: 24523193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.
    Hristodorov D; Mladenov R; Huhn M; Barth S; Thepen T
    Toxins (Basel); 2012 Sep; 4(9):676-94. PubMed ID: 23105975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.